评估套细胞淋巴瘤的真实世界治疗模式与结局
本研究利用美国全国性Flatiron Health电子健康记录去标识数据库,分析2011至2021年4336例套细胞淋巴瘤患者的治疗模式与结局;苯达莫司汀联合利妥昔单抗为最常用一线方案(42%),BTK抑制剂为二线及以后最常用药物(n=933,57%),不同治疗线数下BTK抑制剂治疗者的中位真实世界总生存期分别为35、24和18个月。
要点
- 苯达莫司汀联合利妥昔单抗是最常用一线方案,占42%。
- BTK抑制剂是二线及以后最常用药物,占57%(n=933)。
- BTK抑制剂治疗者一线、二线、三线及以后的中位真实世界总生存期分别为35、24、18个月。
核心结论
- 在真实世界实践中,BTK抑制剂已成为套细胞淋巴瘤二线及以后最常用的药物,且似乎可减轻del17p/TP53突变套细胞淋巴瘤的不良影响(多因素分析HR 1.17,95%CI 0.88-1.55)。
研究设计与样本
- 利用美国全国性Flatiron Health电子健康记录去标识数据库,分析2011至2021年4336例套细胞淋巴瘤患者的真实世界治疗模式与结局。
主要发现
- 苯达莫司汀联合利妥昔单抗是最常用一线方案,占42%。
- 31%的患者接受了利妥昔单抗维持治疗或巩固性自体造血干细胞移植(ASCT)。
- 在接受ASCT作为巩固治疗的患者中,仅34%后续接受了利妥昔单抗维持治疗。
- BTK抑制剂是二线及以后最常用药物(n=933,57%),其次依次为硼替佐米、来那度胺和维奈克拉。
- 接受BTK抑制剂治疗的患者中,一线、二线、三线及以后的中位真实世界总生存期分别为35个月(95%CI 27-50)、24个月(95%CI 22-30)和18个月(95%CI 14-21)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Mantle cell lymphoma (MCL) is considered incurable with the available chemoimmunotherapy approaches, and therefore, newer effective targeted therapies such as Bruton tyrosine kinase (BTK) inhibitors are increasingly used in MCL as chronic suppressive therapy, especially in the elderly. We aimed to describe the treatment patterns in MCL at different lines of therapy with a focus on BTK inhibitor use and compare outcomes with known prognostic factors using a nationwide Flatiron Health electronic health record-derived de-identified database. We analyzed patient-level data from the period of 2011 to 2021. In this study of 4336 patients with MCL, we found that bendamustine plus rituximab chemotherapy was the most commonly used frontline regimen (42%). Maintenance rituximab or consolidative autologous stem cell transplant (ASCT) was administered to 31% of all patients. Also, for patients who received ASCT as consolidation therapy, only 34% subsequently received rituximab maintenance. BTK inhibitors were the most preferred agents in second or later lines of therapy (n = 933, 57%), followed by bortezomib, lenalidomide, and venetoclax, respectively. Among patients treated with BTK inhibitors, the median real-world overall survival (rwOS) was 35 months (95% confidence interval [CI], 27-50), 24 months (95% CI, 22-30), and 18 months (95% CI, 14-21) for first line, second line, and third or later line of therapy, respectively. Patients with a deletion 17p/TP53 mutation and blastoid variant MCL had poor outcomes; however, BTK inhibitors appeared to mitigate the negative influence of del17p/TP53-mutated MCL with a hazard ratio of 1.17 (95% CI, 0.88-1.55) on multivariable analysis.
引用
- Narkhede M, Goyal G, Shea L, et al. Evaluating real-world treatment patterns and outcomes of mantle cell lymphoma. Blood Adv. 2022. PMID: 35561314. doi:10.1182/bloodadvances.2022007247
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。